FOLH1 and cancer: Development of the nomograms outlined at the beginning of this section identified a number of other primarily clinical biomarkers with predictive potential in [177Lu]Lu-PSMA-617 therapy (84), including time since cancer diagnosis; use of opioid analgesic; presence of PSMA-positive lymph node lesions; and levels of hemoglobin, aspartate aminotransferase, lactate dehydrogenase, and alkaline phosphatase (63, 84).